Table 1.
Baseline characteristics of the study patients.
| Variables | Intestinal Behƈet's disease (n = 47) | Crohn's disease (n = 47) | p value |
|---|---|---|---|
| Age (years) | 51.0 ± 11.4 | 36.1 ± 16.0 | < 0.001 |
| Males | 20 (42.6%) | 35 (74.5%) | 0.001 |
| Smoking history | 12 (25.5%) | 11 (23.4%) | 0.810 |
| Disease duration (years) | 7.1 ± 6.0 | 8.0 ± 5.5 | 0.439 |
| Charlson comorbidity index (≥ 2) | 8 (17.0%) | 2 (4.3%) | 0.045 |
| Extraintestinal manifestation | |||
| Oral ulcer | 16 (41.0%) | 0 (0.0%) | < 0.001 |
| Genital ulcer | 11 (28.2%) | 0 (0.0%) | < 0.001 |
| Skin manifestation | 9 (23.1%) | 0 (0.0%) | 0.001 |
| Joint manifestation | 12 (30.8%) | 2 (4.3%) | 0.001 |
| Eye manifestation | 4 (10.3%) | 3 (6.5%) | 0.533 |
| Vascular manifestation | 1 (2.6%) | 0 (0.0%) | 0.459 |
| Perianal lesion | 1 (2.1%) | 28 (59.6%) | < 0.001 |
| Disease activity score | |||
| Remission (CDAI < 150) | 23 (48.9%) | ||
| Mild (CDAI : 150–219) | 10 (21.3%) | ||
| Moderate (CDAI : 220–450) | 13 (27.7%) | ||
| Severe (CDAI > 450) | 1 (2.1%) | ||
| Remission (DAIBD < 20) | 7 (14.9%) | ||
| Mild (DAIBD : 20–39) | 5 (10.6%) | ||
| Moderate (DAIBD : 40–74) | 26 (55.3%) | ||
| Severe (DAIBD ≥ 75) | 1 (2.1%) | ||
| Previous surgery | 10 (21.3%) | 11 (23.4%) | 0.804 |
| Previous medication | |||
| Corticosteroid | 15 (31.9%) | 15 (31.9%) | 1.000 |
| Immunomodulator | 15 (31.9%) | 21 (44.7%) | 0.203 |
| Anti-TNFɑ | 4 (8.5%) | 6 (12.8%) | 0.503 |
Variables are expressed as mean ± SEM or n (%).
BD Behƈet's disease, CD Crohn's disease, TNF tumor necrosis factor, CDAI Crohn's disease activity index, DAIBD disease activity index of Behƈet's disease, SD standard deviation.